Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/28"

Predicate	Value (sorted: default)
rdfs:label	"evidence_1931"
rdf:type	?:Evidence ?:Item
?:Evidence_assump_list_id	"5"
?:Evidence_enzyme_system	""
?:Evidence_type	?:EV_PK_DDI_RCT
?:claim_assumed_valid_for_evidence_application_evidence_1931	?:itraconazole_sole_PK_effect_alter_metabolic_clearance_simvastatin ?:itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4
?:content	"Route of administration: oral polymorphic enzyme: NO study duration: 4 days population: 7 male, 3 female ages:19-29 description: Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
dc:creator	"boycer"
dc:date	"12/07/2007 12:37:19"
rdfs:seeAlso	?:9542477

The resource appears as object in one triple:

{ simvastatin_primary_total_clearance_enzyme_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1931 }

Context graph